OncoMatch/Clinical Trials/NCT06528847
Adjuvant Benmelstobart for Stage IB, Grade 3 Invasive Lung Adenocarcinoma
Is NCT06528847 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Benmelstobart for non-small cell lung cancer.
Treatment: Benmelstobart — This study is a prospective, single-arm, phase 2 clinical trial assessing the feasibility, efficacy, and safety of the PD-L1 inhibitor Benmelstobart (TQB2450) as an adjuvant therapy regimen in patients with pathologic stage IB, IASLC grade 3 invasive lung adenocarcinoma without EGFR active mutations or ALK rearrangement.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: ALK wild-type
Required: PD-L1 (CD274) expression ≥1% (≥1%)
Required: EGFR wild-type
Disease stage
Required: Stage IB
Grade: 3 (iaslc pathology committee 2020)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic chemotherapy
No prior receipt of any anti-tumor treatment, including but not limited to systemic chemotherapy, immunotherapy, or radiotherapy
Cannot have received: immunotherapy
No prior receipt of any anti-tumor treatment, including but not limited to systemic chemotherapy, immunotherapy, or radiotherapy
Cannot have received: radiation therapy
No prior receipt of any anti-tumor treatment, including but not limited to systemic chemotherapy, immunotherapy, or radiotherapy
Cannot have received: immune checkpoint inhibitor
History of using any antibodies or drugs targeting T-cell co-regulatory proteins (immune checkpoints), or previous treatment with anti-tumor vaccines
Cannot have received: anti-tumor vaccine
previous treatment with anti-tumor vaccines
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify